Hemodynamic Monitoring Systems Market - Forecasts from 2024 to 2029

Hemodynamic Monitoring Systems Market - Forecasts from 2024 to 2029

Hemodynamic Monitoring Systems Market was valued at US$942.753 million in 2022 and is expected to grow at a CAGR of 6.01% over the forecast period to reach a market size of US$1418.612 million by 2029.

Hemodynamic monitoring systems take blood pressure readings directly from the veins, heart, and arteries. They also check for blood flow and oxygen levels. These systems also include interfaces for recording diagnostic catheterizations, and coronary, peripheral, and electrophysiology (EP) operations.

The minimally invasive technologies aid in the continuous monitoring of stroke volume and provide dynamic fluid responsiveness information. Some of the systems measure volumetric preload factors, while others use proprietary catheters to continuously monitor central venous saturation.

The growth is being driven by technological advancements in hemodynamic monitoring systems, increased research into hemodynamic monitoring systems, an influx of venture capital funding, a rising prevalence of cardiovascular diseases and diabetes, a rising geriatric population & growing number of surgeries, industry awareness initiatives, and government focus on critical care infrastructure & services.

Market Drivers:

Technological advancements-

With an increasing preference for noninvasive alternatives, Invasive techniques have become less popular in recent years. Noninvasive hemodynamic monitoring technologies allow for painless diagnosis and limit the chance of patients contracting blood-borne diseases. Furthermore, these systems are less invasive and can be operated by a nurse in the absence of a professional or doctor as opposed to invasive systems.

Due to this advantage, the hemodynamic status of multiple patients can be monitored at the same time, resulting in lower staffing and treatment costs. The market for non-invasive systems is likely to grow in the next years due to these benefits. For critically ill patients, noninvasive hemodynamic monitoring requires continuous measurement of blood pressure with finger cuffs and measurement of cardiac output with the pulse contour method. The Caretaker 4 from Caretaker Medical, for example, measures continuous beat-by-beat blood pressure (“cNIBP”), heart rate, and other physiological data with a finger cuff.
Growing cardiovascular diseases-

The market is driven significantly by the increasing prevalence of chronic cardiovascular diseases (CVDs) such as heart failure, coronary artery disease, and arrhythmias. These medical conditions necessitate continuous monitoring of hemodynamic parameters to ensure effective diagnosis, treatment, and management.

According to the World Heart Report, more than half a billion people worldwide are affected by cardiovascular diseases, resulting in 20.5 million deaths in 2021. An unhealthy diet, physical inactivity, tobacco use, and harmful alcohol consumption are identified as the most critical behavioral risk factors for heart disease and stroke.

The rising burden of CVDs is further exacerbated by factors such as a growing geriatric population, unhealthy lifestyles, and increasing rates of obesity. These factors collectively contribute to an escalating demand for hemodynamic monitoring as an essential component in addressing the challenges posed by cardiovascular diseases.

Market Restraint:

Risks involved with invasive hemodynamic monitoring market-

Apart from the discomfort of invasive monitoring (particularly the insertion of the pulmonary artery catheter), there are several risks associated with this procedure: sepsis, bleeding, cardiac arrhythmias, reduced circulation to the distal limb, hemorrhage, nerve damage (during insertion), thrombosis, air embolism, and pulmonary capillary necrosis.

During invasive hemodynamic procedures, these factors increase the fatality rate. Hence, invasive hemodynamic monitoring is only suggested for a limited number of purposes, assuming that the risks are outweighed by the benefits of obtaining relevant data during the procedure.

Furthermore, invasive hemodynamic monitoring methods are not advised for elderly or weak patients. Furthermore, invasive hemodynamic monitoring is very costly and necessitates the use of qualified professionals to place catheters in patients. Even though invasive hemodynamic monitoring gives accurate, comprehensive, and continuous data regarding a patient's hemodynamic state, the risks described above limit its use.

The hemodynamic monitoring systems market is segmented by type into non-invasive, minimally invasive, and invasive

The market for hemodynamic monitoring systems is categorized by type, including non-invasive, minimally invasive, and invasive methods. Non-invasive monitoring is well-suited for continuous monitoring across diverse settings, such as hospital wards, emergency departments, and home care.

Minimally invasive systems are employed for more critically ill patients, typically in intensive care units and during specific medical procedures. Invasive monitoring is reserved for critically ill patients, providing highly accurate and detailed hemodynamic measurements when required.

North America is anticipated to hold a significant share of the hemodynamic monitoring market-

North America is a significant region in the hemodynamic monitoring market and is likely to do so for a few more years. Due to the existence of prominent market participants, technologically advanced hospitals, and an increasing number of critically ill patients being treated in hospitals throughout the region, the hemodynamic monitoring market is expected to develop the most.

The North American hemodynamic monitoring market is likely to increase during the forecast period, thanks to rising FDA approvals for monitoring devices and new product releases.

Market Developments:

July 2023- Retia Medical announced the acquisition of its Argos hemodynamic monitor by Temple University. This acquisition marked a noteworthy milestone for Retia Medical, solidifying its presence in the academic and research communities. The expert medical professionals and researchers at Temple University gained access to the advanced Hemodynamic Monitoring capabilities of the Argos monitor, contributing to the enhancement of patient care.
June 2023- Mindray Medical announced the launch of an advanced hemodynamic monitoring solution in collaboration with Edwards Lifesciences in Europe. This marked a significant milestone in their strategic cooperation agreement. Edwards Lifesciences, a global leader in medical innovations for structural heart disease and critical care monitoring, collaborated with Mindray Medical, a leading medical device and solution provider. The milestone involved integrating the Edwards FloTracTM sensor for hemodynamic monitoring into Mindray's flagship BeneVision N series patient monitors.
June 2022- Clarius Mobile Health, a prominent provider of high-definition wireless ultrasound systems, and ImaCor Inc., a company specializing in hemodynamic ultrasound, announced a partnership that facilitated the introduction of the world's first handheld transesophageal echocardiography (TEE) system. This innovative system was specifically designed for managing and guiding care for critically ill patients in the Intensive Care Unit (ICU). This groundbreaking system received clearance from the U.S. Food and Drug Administration (FDA), empowering clinicians to make informed decisions promptly and accurately, thereby enhancing patient care in the ICU.

Market Segmentation:

By Type
Non-invasive
Minimally-invasive
Invasive
By Product
Monitors
Disposables
By End-user
Hospitals & Clinics
Ambulatory Care Centers
Home Care Settings
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Taiwan
Thailand
Indonesia
Others